Solt DB is a public benefit company exploring the intersection of biology and finance. Our platform has three segments: investing (subscription), writing, and data. Solt DB Invest analyzes biotech stocks. We leverage a bottom-up research approach to model the fair valuation of biotech businesses such as Ginkgo Bioworks and Twist Bioscience. Then we show you, in real time, how much each stock must rise or fall to reach our estimate. Subscribers gain access to more and better information to make more intelligent investing decisions – and 65% have a STEM background. Subscriptions to investment research allow us to provide original, high-quality content for free. Our independent journalism and analysis of the bioeconomy leans on executive interviews, interdisciplinary domain expertise, and Freedom of Information Act (FOIA) requests. We're also building the Solt DB Biotech Company Database. The finch's ambitious goal is for this data asset to become the world's only historical record of every company in the global bioeconomy. As part of our public benefit, Solt DB is committed to keeping the database free and open as a public resource.
